Disseminated Ureaplasma Urealyticum Infection in MS Patients on Ocrelizumab
Two female patients with multiple sclerosis (MS) on ocrelizumab developed a widespread Ureaplasma urealyticum infection, which was wrongly diagnosed as reactive arthritis at first. After receiving extended treatment with antibiotics and glucocorticoids, both patients showed resolution of the infection.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Limited
- Outcome
- Not reported
Why it matters
This case highlights the potential for misdiagnosis of infections in MS patients receiving immunosuppressive therapy like ocrelizumab, which is crucial for preventing complications in similar cases.
What this does not prove
The findings are based on only two cases and may not be applicable to a broader population.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Case report
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-07-26
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- 38-year-old female of South Asian descent and a 46-year-old White female, both with MS on ocrelizumab
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceDisseminated Ureaplasma urealyticum infection presenting as systemic inflammatory syndrome in ocrelizumab-treated patients with multiple sclerosis: a case series. ↗DOI: 10.1186/s13256-026-06256-9
Supporting passages (9)
study designPublication types: Journal Article; Case Reports
subjectsTitle: Disseminated Ureaplasma urealyticum infection presenting as systemic inflammatory syndrome in ocrelizumab-treated patients with multiple sclerosis: a case series.
populationCASE PRESENTATION: A 38-year-old female of South Asian descent and a 46-year-old White female, both with MS on ocrelizumab, developed disseminated Ureaplasma urealyticum infection which was initially misdiagnosed as reactive arthritis in both cases.
findingsProlonged antimicrobial and glucocorticoid therapy led to resolution in both cases.
publication datePublication date: 2026-07-26
limitationsTitle: Disseminated Ureaplasma urealyticum infection presenting as systemic inflammatory syndrome in ocrelizumab-treated patients with multiple sclerosis: a case series.
peer reviewedPublication types: Journal Article; Case Reports
subjectsMeSH terms: Humans; Female; Middle Aged; Ureaplasma Infections; Adult; Multiple Sclerosis; Ureaplasma urealyticum; Antibodies, Monoclonal, Humanized; Opportunistic Infections; Endophthalmitis; Anti-Bacterial Agents; Treatment Outcome; Arthritis, Reactive; Glucocorticoids
subjectsPublication types: Journal Article; Case Reports
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.